Novel Approaches in Genetic Characterization and Targeted Therapy for Brain Metastases

被引：0

作者：

Castro, Brandyn A. ^{[1
,2
]}

Kuang, Ruby ^{[1
,2
]}

Brastianos, Priscilla K. ^{[1
,2
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol Surg, Boston, MA 02114 USA

来源：

DISCOVERY MEDICINE | 2016年 / 22卷 / 122期

关键词：

CELL LUNG-CANCER; CENTRAL-NERVOUS-SYSTEM; TYROSINE KINASE INHIBITORS; LAPATINIB PLUS CAPECITABINE; PHASE-II TRIAL; FACTOR RECEPTOR MUTATIONS; ADVANCED BREAST-CANCER; EML4-ALK FUSION GENE; RADIATION-THERAPY; OPEN-LABEL;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Metastases to the brain are a common complication of various cancers and are associated with poor prognosis. Management of these patients requires a multidisciplinary approach including whole-brain radiation therapy, stereotactic radiosurgery, surgical resection, chemotherapy, and supportive treatment. Because of recent technological advancements in genomics, our understanding of the genetics of brain metastases is rapidly advancing. This has led to the discovery of many potential genetic therapeutic targets in metastatic brain lesions. One of the limitations to systemic therapies is their limited ability to cross the blood brain barrier, necessitating the urgency to develop clinical trials to evaluate efficacy. A description of these genetic mutations, targeted therapies, and associated clinical trials in brain metastases from lung cancers, breast cancers, and melanoma is outlined in this review.

引用

页码：237 / 250

页数：14

共 148 条

[51]

Han L, 2013, INT J CLIN EXP PATHO, V6, P2357

[52] Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial [J].

Hauschild, Axel ;

Grob, Jean-Jacques ;

Demidov, Lev V. ;

Jouary, Thomas ;

Gutzmer, Ralf ;

Millward, Michael ;

Rutkowski, Piotr ;

Blank, Christian U. ;

Miller, Wilson H., Jr. ;

Kaempgen, Eckhart ;

Martin-Algarra, Salvador ;

Karaszewska, Boguslawa ;

Mauch, Cornelia ;

Chiarion-Sileni, Vanna ;

Martin, Anne-Marie ;

Swann, Suzanne ;

Haney, Patricia ;

Mirakhur, Beloo ;

Guckert, Mary E. ;

Goodman, Vicki ;

Chapman, Paul B. .

LANCET, 2012, 380 (9839) :358-365

[53] The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations [J].

Heon, Stephanie ;

Yeap, Beow Y. ;

Lindeman, Neal I. ;

Joshi, Victoria A. ;

Butaney, Mohit ;

Britt, Gregory J. ;

Costa, Daniel B. ;

Rabin, Michael S. ;

Jackman, David M. ;

Johnson, Bruce E. .

CLINICAL CANCER RESEARCH, 2012, 18 (16) :4406-4414

[54] Receptor conversion in distant breast cancer metastases [J].

Hoefnagel, Laurien D. C. ;

van de Vijver, Marc J. ;

van Slooten, Henk-Jan ;

Wesseling, Pieter ;

Wesseling, Jelle ;

Westenend, Pieter J. ;

Bart, Joost ;

Seldenrijk, Cornelis A. ;

Nagtegaal, Iris D. ;

Oudejans, Joost ;

van der Valk, Paul ;

van der Groep, Petra ;

de Vries, Elisabeth G. E. ;

van der Wall, Elsken ;

van Diest, Paul J. .

BREAST CANCER RESEARCH, 2010, 12 (05)

[55] Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Pretreated Non-Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease [J].

Hoffknecht, Petra ;

Tufman, Amanda ;

Wehler, Thomas ;

Pelzer, Theo ;

Wiewrodt, Rainer ;

Schuetz, Martin ;

Serke, Monika ;

Stoehlmacher-Williams, Jan ;

Maerten, Angela ;

Huber, Rudolf Maria ;

Dickgreber, Nicolas J. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) :156-163

[56] NRAS mutation status is an independent prognostic factor in metastatic melanoma [J].

Jakob, John A. ;

Bassett, Roland L., Jr. ;

Ng, Chaan S. ;

Curry, Jonathan L. ;

Joseph, Richard W. ;

Alvarado, Gladys C. ;

Rohlfs, Michelle L. ;

Richard, Jessie ;

Gershenwald, Jeffrey E. ;

Kim, Kevin B. ;

Lazar, Alexander J. ;

Hwu, Patrick ;

Davies, Michael A. .

CANCER, 2012, 118 (16) :4014-4023

[57] Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology [J].

Jänne, PA ;

Engelman, JA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3227-3234

[58] PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis [J].

Jilaveanu, Lucia B. ;

Parisi, Fabio ;

Barr, Meaghan L. ;

Zito, Christopher R. ;

Cruz-Munoz, William ;

Kerbel, Robert S. ;

Rimm, David L. ;

Bosenberg, Marcus W. ;

Halaban, Ruth ;

Kluger, Yuval ;

Kluger, Harriet M. .

CLINICAL CANCER RESEARCH, 2015, 21 (09) :2138-2147

[59]

Keith Kevin C, 2016, Cancer Treat Commun, V7, P43

[60] Metastatic Behavior of Breast Cancer Subtypes [J].

Kennecke, Hagen ;

Yerushalmi, Rinat ;

Woods, Ryan ;

Cheang, Maggie Chon U. ;

Voduc, David ;

Speers, Caroline H. ;

Nielsen, Torsten O. ;

Gelmon, Karen .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3271-3277

← 1 2 3 4 5 6 7 8 9 10 →